LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.
about
Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapyRethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerCIViC databaseMolecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and TreatmentIntegrated genomic characterization of endometrial carcinomaPhylogenetic quantification of intra-tumour heterogeneitySpatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysisNCI Workshop Report: Clinical and Computational Requirements for Correlating Imaging Phenotypes with Genomics SignaturesRevealing cancer subtypes with higher-order correlations applied to imaging and omics dataRadiogenomics of High-Grade Serous Ovarian Cancer: Multireader Multi-Institutional Study from the Cancer Genome Atlas Ovarian Cancer Imaging Research Group.VCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancerThe integrated landscape of driver genomic alterations in glioblastoma.Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments.Very large common fragile site genes and their potential role in cancer development.WWOX, large common fragile site genes, and cancer.Recently identified drug resistance biomarkers in ovarian cancer.Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription.Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy.Common fragile sites (CFS) and extremely large CFS genes are targets for human papillomavirus integrations and chromosome rearrangements in oropharyngeal squamous cell carcinoma.New horizons for lipoprotein receptors: communication by β-propellers.Expression of a recombinant full-length LRP1B receptor in human non-small cell lung cancer cells confirms the postulated growth-suppressing function of this large LDL receptor family member.Regulatory network involving miRNAs and genes in serous ovarian carcinoma.RNA-seq Based Transcription Characterization of Fusion Breakpoints as a Potential Estimator for Its Oncogenic Potential.Acquired chemotherapy resistance in ovarian cancer.Whole-genome characterization of chemoresistant ovarian cancer.Single nucleotide variant profiles of viable single circulating tumour cells reveal CTC behaviours in breast cancer.Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer
P2860
Q26769604-5A326DCF-501B-46E1-B23C-A35390E96501Q26780387-33294EBC-56A4-4159-8F05-5C6BB45FB3A4Q27612411-A872FB78-73E7-482B-913A-C78D7B641044Q28066904-8B3B0CFA-EA13-4D56-9EBD-0492399EFB84Q28289962-111556A9-BFD9-4173-879A-9640B5DA1F8FQ28537974-71058B45-8C98-4A20-A4B3-2AC2B089A3F9Q28649475-BFE9A9FA-7668-47D1-921B-0F3DF94BE652Q34478588-E2CC96B1-AAF8-4E0F-AA5E-DD4359767CDEQ36328777-8A53A5D6-28B5-4EB1-AB37-FE94FE695CF6Q36412660-26693690-F1F1-4C65-9902-CD3D6DA5DFBBQ36789013-A2B2D4ED-14D7-45AB-80BA-EFC2F4917220Q37237987-00B8B85E-9027-411C-ADD9-F2103FD4BA65Q37395388-D7FAB4B3-F23E-4020-9ABC-03B3D844104AQ37504931-D7F4D12C-6CD0-468A-8E25-4A257712814CQ38205584-1D4A0CCD-5064-477A-B730-AFDC38B22D65Q38258543-A27A46A9-6E45-460C-85BD-EDC2CCC08382Q38321093-A4F7EB69-2720-48E5-AFEA-DDBF821B1FB4Q38741073-FA106959-175D-4A3C-913A-9A31249AF4E3Q38796545-AC94BBD4-9D9C-4114-9A03-A2F2253EF2B1Q39350074-F1C09F9A-D428-4885-8596-9203828401C0Q40172727-B2E9973B-FAF7-4E4D-A7AC-1CCB0BFBE919Q40473479-9B4845B5-DA60-4031-A7E0-27B170D1D377Q42105665-CE188329-396D-4BBE-979B-B0372BB22BAFQ42315536-DB091DE1-0737-4531-B682-8EBC4D00E53FQ45874094-1AE4B9B7-DAAE-4105-8030-18A129A4A050Q45943536-E9DEF2E2-83B7-4D56-ADD4-CC31A2BBD016Q49896015-BFA5AB4A-EB32-45A7-AD78-243FFAD4048AQ50272478-6C4767D2-470B-4EFB-AE11-D516B5487A8AQ52724992-2CC2DEBC-B1DC-4449-B268-911DFC902B72Q58701464-7C97008C-A470-4C50-9938-59389AEB765C
P2860
LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
LRP1B deletion in high-grade s ...... ance to liposomal doxorubicin.
@ast
LRP1B deletion in high-grade s ...... ance to liposomal doxorubicin.
@en
LRP1B deletion in high-grade s ...... ance to liposomal doxorubicin.
@nl
type
label
LRP1B deletion in high-grade s ...... ance to liposomal doxorubicin.
@ast
LRP1B deletion in high-grade s ...... ance to liposomal doxorubicin.
@en
LRP1B deletion in high-grade s ...... ance to liposomal doxorubicin.
@nl
prefLabel
LRP1B deletion in high-grade s ...... ance to liposomal doxorubicin.
@ast
LRP1B deletion in high-grade s ...... ance to liposomal doxorubicin.
@en
LRP1B deletion in high-grade s ...... ance to liposomal doxorubicin.
@nl
P2093
P50
P1433
P1476
LRP1B deletion in high-grade s ...... ance to liposomal doxorubicin.
@en
P2093
Dariush Etemadmoghadam
Joshy George
Joy Hendley
Laura Galletta
Leanne Bowes
Michael Friedlander
Orla McNally
Peter Campbell
Prue A Cowin
Richard B Pearson
P304
P356
10.1158/0008-5472.CAN-12-0203
P407
P50
P577
2012-08-15T00:00:00Z